Safety of rasagiline in elderly patients with Parkinson disease.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 16682679.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The authors examined age effects on adverse events from two randomized, controlled trials of rasagiline, comparing younger (younger than 70 years) and older (70 years and older) subjects. Older patients were more prone to serious adverse effects than younger patients, but there was no statistical interaction between age and rasagiline exposure. This absence of an age-rasagiline interaction suggests that rasagiline does not require special safety precautions for elderly subjects with Parkinson disease.
Medical subject headings
- Antiparkinson Agents
- Confusion
- Disorders of Excessive Somnolence
- Hypotension, Orthostatic
- Indans
- Monoamine Oxidase Inhibitors
- Parkinson Disease